A single nucleotide polymorphism in the matrix metalloproteinase 9 gene (-8202A/G) is associated with thoracic aortic aneurysms and thoracic aortic dissection.

[1]  B. Iacopetta,et al.  Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype , 2004, Breast Cancer Research and Treatment.

[2]  G. Johnson,et al.  Nature Encyclopedia of the Human Genome , 2004 .

[3]  Gregory T. Jones,et al.  Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. , 2003, Journal of vascular surgery.

[4]  S. Scherer,et al.  Mapping a Locus for Familial Thoracic Aortic Aneurysms and Dissections (TAAD2) to 3p24–25 , 2003, Circulation.

[5]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[6]  A. Morgan,et al.  Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease , 2003, Journal of Molecular Medicine.

[7]  B. Baxter,et al.  Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. , 2002, Journal of vascular surgery.

[8]  B. Baxter,et al.  Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. , 2002, Journal of vascular surgery.

[9]  Constance E. Brinckerhoff,et al.  Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.

[10]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[11]  K. Angquist,et al.  Proteolysis of the abdominal aortic aneurysm wall and the association with rupture. , 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[12]  M. Leinonen,et al.  Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. , 2001, Journal of vascular surgery.

[13]  D. Spina,et al.  Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. , 2001, Human pathology.

[14]  E. Boerwinkle,et al.  Familial Thoracic Aortic Aneurysms and Dissections: Genetic Heterogeneity With a Major Locus Mapping to 5q13-14 , 2001, Circulation.

[15]  D. Milewicz,et al.  Identification of a Chromosome 11q23.2-q24 Locus for Familial Aortic Aneurysm Disease, a Genetically Heterogeneous Disorder , 2001, Circulation.

[16]  T. Noma,et al.  Enhanced Expression of Matrix Metalloproteinase-9 in Abdominal Aortic Aneurysms , 2001, World Journal of Surgery.

[17]  D. Hovsepian,et al.  Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. , 2000, Journal of vascular and interventional radiology : JVIR.

[18]  J. Lindholt,et al.  The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[19]  T Ishii,et al.  Collagen and elastin degradation by matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in aortic dissection. , 2000, Human pathology.

[20]  B. Rubin,et al.  Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. , 2000, Journal of vascular surgery.

[21]  B. Baxter,et al.  MMP Inhibition in Abdominal Aortic Aneurysms: Rationale for a Prospective Randomized Clinical Trial , 1999, Annals of the New York Academy of Sciences.

[22]  W. Pearce,et al.  Size matters: the relationship between MMP-9 expression and aortic diameter. , 1997, Circulation.

[23]  W. Pearce,et al.  Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. , 1997, Surgery.

[24]  R. Mecham,et al.  Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. , 1995, The Journal of clinical investigation.

[25]  J. Powell,et al.  Cellular, enzymatic, and genetic factors in the pathogenesis of abdominal aortic aneurysms. , 1989, Journal of vascular surgery.

[26]  J. Coselli,et al.  Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves. , 2005, The Journal of surgical research.

[27]  Kazuhiro Yoshida,et al.  A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[28]  David Neil Cooper,et al.  Nature encyclopedia of the human genome , 2003 .

[29]  W. Pearce,et al.  Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. , 1999, Journal of vascular surgery.

[30]  R. Badenhop,et al.  A smoking–dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene , 1996, Nature Medicine.